Schering Gene Therapy Terminal Population Supports Trial Continuation
The extremely ill patient population in Schering-Plough's study of SCH 58500 adenoviral vector-based gene therapy is one factor supporting continued enrollment in its liver cancer studies, the company told NIH's Recombinant DNA Advisory Committee Dec. 8.
You may also be interested in...
FDA and NIH would receive harmonized adverse event reports from gene therapy trial sponsors under a Biotechnology Industry Organization proposal.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011